Adding perioperative tislelizumab to neoadjuvant chemotherapy and surgery can improve outcomes in patients with NSCLC, a phase 3 trial suggests.
News
The kinase inhibitor was previously approved for this indication under the FDA’s accelerated pathway based on overall response rate and duration of response.
Adding pegargiminase to standard chemotherapy can improve outcomes in patients with chemotherapy-naïve, nonepithelioid pleural mesothelioma, data suggest.
The application is supported by data from the phase 3 CheckMate -77T trial which included 452 treatment-naive patients with resectable stage IIA to IIIB NSCLC.
Investigators sought to determine the use of comprehensive genome profiling in patients with advanced NSCLC related to time of diagnosis and the effect on receipt targeted treatment.
For resectable early-stage NSCLC, improved event-free survival seen with pembrolizumab, regardless of N status, clinical stage, type of surgery.
Perioperative nivolumab can improve event-free survival in patients with stage II-IIIB non-small cell lung cancer receiving neoadjuvant chemotherapy and surgery, a phase 3 trial suggests.
US lung cancer incidence and mortality rates continue to decline, but disparities remain across sexes and racial/ethnic groups.
Adding serplulimab to first-line chemotherapy improved survival outcomes in a phase 3 trial of patients with advanced NSCLC.
However, few individuals with newly diagnosed lung cancer engage in daily moderate-to-vigorous physical activity.